Biodistribution and dosimetry of the investigational PET agent 68Ga-P16-093 in prostate cancer patients with biochemical recurrence undergoing clinical 68Ga-PSMA-11 PET/CT
M
Mark Green
Primary Investigator
Overview
Whole body biodistribution and dosimetry with preliminary comparison to PSMA-11 in prostate cancer patients with biochemical recurrence
Description
The primary purpose of the present research project is to determine the biodistribution of 68Ga-P16-093 in prostate cancer patients, and to assess associated patient radiation exposure based on our PET measures of organ uptake as a function of time. A secondary goal is to conduct a preliminary evaluation of the sensitivity and specificity of 68Ga-P16-093 compared to 68Ga-PSMA-11 to detect local or distant sites of recurrent disease.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
prostate cancer
-
Age: Between 18 Years - 100 Years
-
Gender: Male
Inclusion Criteria
Prostate cancer patients presenting with rising PSA after radical prostatectomy for treatment if primary disease
Histologically confirmed prostate cancer with following Gleason scoring at biopsy
Scheduled for radical prostatectomy (expected to occur within 60-days of scanning)
Exclusion Criteria
Exclusion Criteria
Patient is unable to tolerate remaining still on the bed of the PET camera, due to physical limitations or claustrophobia
Significant acute or chronic medical, neurologic, or illness in the subject that, in the judgment of the Clinical Investigators, could compromise subject safety, limit the ability to complete the study, and/or compromise the objectives of the study
Additional Information:
Updated on
19 Apr 2024.
Study ID: 1711061247 (RADY-FIVEELEV-GREEN-GA)
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
